Combining Vemurafenib and Metformin for Melanoma Treatment
Author Information
Author(s): Franziska Niehr, Erika Euw, Narsis Attar, Deliang Guo, Doug Matsunaga, Hooman Sazegar, Charles Ng, John A Glaspy, Juan A Recio, Roger S Lo, Paul S Mischel, Begonya Comin-Anduix, Antoni Ribas
Primary Institution: University of California Los Angeles (UCLA)
Hypothesis
The combination of BRAF oncogene inhibition and metabolic modulation of AMPK would be more effective than either manipulation alone in arresting melanoma cell proliferation.
Conclusion
The combination of vemurafenib and metformin showed stronger anti-proliferative effects on BRAFV600E mutant cell lines, but the reasons for varying responses need further investigation.
Supporting Evidence
- Single agent metformin inhibited proliferation in 12 out of 19 cell lines.
- The combination showed synergistic effects in 6 out of 11 BRAFV600E mutants.
- Antagonistic effects were noted in some cell lines resistant to vemurafenib.
Takeaway
Researchers tested two drugs, vemurafenib and metformin, to see if using them together would work better against melanoma than using them alone. They found that sometimes it worked well, but not always.
Methodology
The study tested the effects of vemurafenib and metformin on melanoma cell lines with specific mutations, measuring cell viability, cell cycle, and apoptosis.
Limitations
The study did not fully explain the differential effects observed in various cell lines, and the combination did not reverse resistance in some cases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website